Daiichi to tie up with GlaxoSmithKline in Japan: report
(Reuters) - Daiichi Sankyo Co (4568.T), Japan's No.3 drugmaker, will tie up with Britain's pharmaceutical giant GlaxoSmithKline plc (GSK.L) to bring new products to the Japanese market, the Nikkei reported.
Daiichi and GSK's local unit, which will form a 50-50 joint venture in Japan, will initially sell key products of both firms, such as GSK's cervical cancer vaccine and Daiichi's influenza vaccine, the Japanese daily reported.
The companies' plan calls for the joint development and quick launch of products not available in Japan, such as a shingles vaccine, as well as combination vaccines against multiple illnesses, the paper said.
Japan had an estimated 140 billion yen ($1.73 billion) vaccine market in 2010, Nikkei said.
A tie-up with GSK, whose vaccine sales in Japan totaled about 60 billion yen last year, will help Daiichi expand in the field positioned as a key business, the daily reported.
($1 = 80.9400 Japanese yen)
(Reporting by Sagarika Jaisinghani in Bangalore; Editing by Supriya Kurane)
NEW YORK - Stocks rose on Friday, capping the best week for major indexes in months as unexpectedly strong data on economic growth increased confidence that the recovery was accelerating. | Video
WASHINGTON - Start-up companies will be able to raise much more capital through certain public stock deals without facing costly regulatory burdens under a proposal announced by U.S. securities regulators on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.